Edap Tms (NASDAQ:EDAP) Stock Price Passes Above Two Hundred Day Moving Average – Here’s Why
Edap Tms (NASDAQ:EDAP) shares rose 2.9% and crossed above its 200-day moving average, trading up to $4.47 and last at $4.32. The 200-day average was $3.59. Analysts cited include HC Wainwright cutting its target to $10 (buy) and Wall Street Zen changing to sell; MarketBeat reports consensus hold and $6 target. In May 7 results, EPS was ($0.24) vs ($0.22) expected and revenue was $20.48M vs $19.46M.
How this was made
The 30-second read
Why it matters
Near-term trading interest is driven by (1) the stock reclaiming its 200-day moving average, (2) a recent earnings print that missed EPS but beat revenue, and (3) conflicting analyst calls (target cut by one firm, consensus still “Hold”). Insider buying and institutional accumulation are supportive but not decisive without a new fundamental catalyst.
Market read
This is a single-name momentum/positioning story with some fundamental context (recent earnings and analyst target dispersion), suitable for tactical trading around the 200-day level.
What to watch
The article highlights a director buy and institutional ownership, but it doesn’t quantify liquidity/float changes or order-flow; traders should verify whether the breakout is supported by sustained volume beyond 55,873 shares.
Background
EDAP is a France-based medical device company focused on noninvasive urology therapies (HIFU for prostate tissue ablation and shock-wave lithotripsy). The article frames Friday’s move as a technical breakout and then summarizes recent earnings and analyst actions.
Ticker impact
EDAP shares crossed above the 200-day moving average and the article cites recent analyst target changes and its latest earnings miss.
Choppy-to-positive near-term bias while price holds above the 200-day (~$3.59) and analysts’ target dispersion keeps volatility elevated.
The article provides a concrete technical level (200-day MA) and fresh datapoints (recent earnings results, analyst target cuts/ratings, director buy). However, it lacks new operational/regulatory catalysts beyond the already-reported earnings date.
Market effects
Limited sector read-through; this is primarily a single-name technical/positioning update for a medical device company.
No explicit regional macro/regulatory catalyst; largely US-listed microstructure/positioning.
Low—no mention of global deal/regulatory decisions affecting the broader medtech complex.
Counterpoint
A 200-day cross can be a lagging signal; with negative net margin and consensus “Hold,” the move could fade if follow-through volume is weak.
Key entities
- public_companyEDAP
NASDAQ-listed medical device company; stock crossed above its 200-day moving average and had a recent EPS miss with revenue beat.
- insiderJoshua Levine
Director who bought 10,000 shares at an average price of $4.22 (Form 4 disclosure referenced).
